KeyBanc raises ResMed stock price target on FY27 outlook confidence
Covered in this story
What has happened since
- ResMed is up 2.2% since this was published, 50 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
KeyBanc Capital Markets’s $267 target on $RMD is on the record and being tracked to Aug 2027 (12-month default), scored on the close that day.
KeyBanc Capital Markets’s track record →Analyst targets on ResMed
- Stifel: $219 → $235 by Oct 2027 · Hold via Investing.com
- RBC Capital Markets: $229 → $262 by Sep 2027 · Outperform via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $RMD yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on ResMed →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.